Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tarlatamab - Amgen

Next Previous
Drug Profile

Tarlatamab - Amgen

Alternative Names: AMG-757; IMDELLTRA; Imdelltra; IMDYLLTRA; Tarlatamab-dlle

Latest Information Update: 24 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; BeOne Medicines
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Phase I/II Glioma
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 21 Nov 2025 Discontinued - Phase-I for Prostate cancer (Metastatic disease, Second-line therapy or greater) in Australia, Austria, Japan, Spain, USA, Belgium, France, Netherlands, United Kingdom (IV) (Amgen pipeline, November 2025)
  • 19 Nov 2025 Tarlatamab receives full approval for Small cell lung cancer in USA
  • 04 Nov 2025 Phase-I/II clinical trials in Glioma (Combination therapy, In adolescents, In adults, In the elderly) in France (IV) (NCT07243470)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top